Literature DB >> 22999944

Redefining the viral reservoirs that prevent HIV-1 eradication.

Evelyn Eisele1, Robert F Siliciano.   

Abstract

This Perspective proposes definitions for key terms in the field of HIV-1 latency and eradication. In the context of eradication, a reservoir is a cell type that allows persistence of replication-competent HIV-1 on a timescale of years in patients on optimal antiretroviral therapy. Reservoirs act as a barrier to eradication in the patient population in which cure attempts will likely be made. Halting viral replication is essential to eradication, and definitions and criteria for assessing whether this goal has been achieved are proposed. The cell types that may serve as reservoirs for HIV-1 are discussed. Currently, only latently infected resting CD4(+) T cells fit the proposed definition of a reservoir, and more evidence is necessary to demonstrate that other cell types, including hematopoietic stem cells and macrophages, fit this definition. Further research is urgently required on potential reservoirs in the gut-associated lymphoid tissue and the central nervous system.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999944      PMCID: PMC3963158          DOI: 10.1016/j.immuni.2012.08.010

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  140 in total

1.  Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain.

Authors:  Tahar Babas; Daniel Muñoz; Joseph L Mankowski; Patrick M Tarwater; Janice E Clements; M Christine Zink
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

3.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

Review 4.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

5.  Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages.

Authors:  Brandon L Walter; Kathy Wehrly; Ronald Swanstrom; Emily Platt; David Kabat; Bruce Chesebro
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells.

Authors:  Nichole R Klatt; Emi Shudo; Alex M Ortiz; Jessica C Engram; Mirko Paiardini; Benton Lawson; Michael D Miller; James Else; Ivona Pandrea; Jacob D Estes; Cristian Apetrei; Joern E Schmitz; Ruy M Ribeiro; Alan S Perelson; Guido Silvestri
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

9.  In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.

Authors:  Joseph K Wong; Matthew C Strain; Rodin Porrata; Elizabeth Reay; Sumathi Sankaran-Walters; Caroline C Ignacio; Theresa Russell; Satish K Pillai; David J Looney; Satya Dandekar
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

10.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

View more
  213 in total

1.  Simian Immunodeficiency Virus SIVsab Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research.

Authors:  Dongzhu Ma; Cuiling Xu; Anthony R Cillo; Benjamin Policicchio; Jan Kristoff; George Haret-Richter; John W Mellors; Ivona Pandrea; Cristian Apetrei
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

Review 2.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

3.  Hematopoietic cell transplantation and HIV cure: where we are and what next?

Authors:  Shimian Zou; Simone Glynn; Daniel Kuritzkes; Monica Shah; Nakela Cook; Nancy Berliner
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

4.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 5.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

6.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

Review 7.  The multifaceted nature of HIV latency.

Authors:  Caroline Dufour; Pierre Gantner; Rémi Fromentin; Nicolas Chomont
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

8.  Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.

Authors:  Ajay Singh; Hilliard L Kutscher; Julia C Bulmahn; Supriya D Mahajan; Guang S He; Paras N Prasad
Journal:  Nanomedicine       Date:  2020-02-13       Impact factor: 5.307

9.  HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.

Authors:  Joshua A Horwitz; Ariel Halper-Stromberg; Hugo Mouquet; Alexander D Gitlin; Anna Tretiakova; Thomas R Eisenreich; Marine Malbec; Sophia Gravemann; Eva Billerbeck; Marcus Dorner; Hildegard Büning; Olivier Schwartz; Elena Knops; Rolf Kaiser; Michael S Seaman; James M Wilson; Charles M Rice; Alexander Ploss; Pamela J Bjorkman; Florian Klein; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

10.  Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.

Authors:  Koen Bartholomeeusen; Koh Fujinaga; Yanhui Xiang; B Matija Peterlin
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.